BIOMAT Database Logo BIOMAT Database Logo

Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. 1988

A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Nephrology Service, Hospital Clínic i Provincial, Barcelona, Spain.

We report 5 cases of acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Four patients complained of visual toxicity characterized by a decrease in visual acuity, loss of color vision and night blindness. In these patients there was a decrease in visual acuity, and the Farnsworth's test revealed a tritanopy (yellow-blue axis impairment); 1 patient also showed retinal pigmentary changes. A fifth patient complained of bilateral and severe neurosensorial deafness. Patients improved clinically upon drug-withdrawal. We recommend careful monitoring of audiovisual toxicity in patients with end-stage renal disease receiving this drug.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D005260 Female Females
D006312 Hearing Loss, Bilateral Partial hearing loss in both ears. Deafness Bilateral,Bilateral Deafness,Bilateral Hearing Loss,Bilateral Hearing Losses,Bilateral, Deafness,Bilaterals, Deafness,Deafness Bilaterals,Deafness, Bilateral,Loss, Bilateral Hearing
D006319 Hearing Loss, Sensorineural Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM. Deafness Neurosensory,Deafness, Neurosensory,Deafness, Sensoryneural,Neurosensory Deafness,Sensorineural Hearing Loss,Sensoryneural Deafness,Cochlear Hearing Loss,Hearing Loss, Cochlear,Deafnesses, Neurosensory,Deafnesses, Sensoryneural,Neurosensory Deafnesses,Sensoryneural Deafness,Sensoryneural Deafnesses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
July 1989, Clinical nephrology,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
April 1986, The New England journal of medicine,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Valacyclovir Neurotoxicity in Patients with End-Stage Renal Disease: Two Cases Reviewed.
February 2024, Journal of pharmacy practice,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
YKL-40 in patients with end-stage renal disease receiving haemodialysis.
January 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Subdural hematoma in patients with end-stage renal disease receiving hemodialysis.
June 2014, European journal of neurology,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Neurotoxicity of acyclovir in end stage renal disease.
February 1990, The Journal of antimicrobial chemotherapy,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Acute appendicitis in patients with end-stage renal disease.
October 2012, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Leftward Bias of Visual Attention in Patients with End-Stage Renal Disease Receiving Dialysis: A Neglected Phenomenon.
December 2017, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Clinical Oral Findings in Patients With End-stage Renal Disease Receiving Hemodialysis.
May 2015, The Journal of craniofacial surgery,
A Cases, and J Kelly, and J Sabater, and J M Campistol, and A Torras, and J Montoliu, and I López, and L Revert
Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
June 2000, Pharmacotherapy,
Copied contents to your clipboard!